http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-073872-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| filingDate | 2009-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-073872-A1 |
| titleOfInvention | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST, METHOD TO TREAT A PATIENT, DEVICE AND KIT |
| abstract | Claim 1: A medicament comprising at least one insulin and at least one GLP-1 agonist, wherein the medicament is formulated and / or prepared in a manner that comprises insulin and the GLP-1 agonist, each in a predetermined amount and can be administered in a dose adapted to the individual requirement of a patient. Claim 14: A medicament claimed according to any of the preceding claims, wherein the at least one insulin is independently selected from human insulins, their analogues, derivatives, and metabolites. Claim 15: A medicament claimed according to claim 14, wherein the at least one insulin is independently selected from the group consisting of Gly (A21) -Arg (B31) -Arg (B32) human insulin, LysB28ProB29, human insulin, B28 Asp human insulin, and B29Lys (? -Tetradecanoyl), desB30 human insulin. Claim 16: A medicament claimed according to any of the preceding claims, wherein the at least one GLP-1 agonist is independently selected from the group consisting of GLP-1, its analogues and derivatives, exendin-3, its analogues and exendin-4 derivatives, their analogues and derivatives, and their pharmacologically tolerable salts. Claim 17: A medicament claimed according to claim 16, wherein the at least one GLP-1 agonist is independently selected from the group consisting of exendin-4, desPro36exendina-4 (1-39) -Lys6-NH2 [AVE0010 ], and Arg34, Lys26 (N? (? - gtutamil (Nalfa-hexadecanoyl))) GLP-1 (7-37) [liraglutide], and its pharmacologically tolerable salts. Claim 23: The use of at least one insulin and at least one GLP-1 agonist to prepare a medicinal product to treat a patient with diabetes, more particularly type 1 or 2 diabetes, to adjust the fasting blood glucose concentration, postprandial and / or post-absorptive, to improve glucose tolerance, to prevent hypoglycemia, to prevent loss of pancreatic beta cell function, for weight loss and / or to prevent weight gain. |
| priorityDate | 2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.